event tracking

Neuro­degenerative Science

Overview

Department of Neurodegenerative Science

Worldwide, between 7 million and 10 million people have Parkinson’s disease and more than 30 million have dementia. Currently, there is no cure and no effective way to slow or stop disease progression.

VAI scientists aim to change that by investigating the complex factors that give rise to neurodegenerative and psychiatric disorders, from genetics and epigenetics to aging, inflammation and the structure of the brain itself — even the role of the gut and the immune system. By leveraging discoveries made in VAI’s labs and collaborating with researchers around the world, our scientists are working to translate breakthroughs into life-changing new treatments for Parkinson’s, dementias and depression.

West Michigan Neurodegenerative Diseases (MiND) Program

Van Andel Institute’s West Michigan Neurodegenerative Diseases (MiND) Program is a collaborative effort to identify genetic and epigenetic changes that may play roles in neurodegenerative diseases, such as Parkinson’s and dementias. Our goal? To move the needle in our understanding of these diseases, power new discoveries and leverage our findings to inform groundbreaking treatment strategies.

Explore MiND Program

Our Faculty

Darren Moore, Ph.D.

Chair and Professor, Department of Neurodegenerative Science; Director, MiND Program; Jay Van Andel Endowed Chair in Parkinson’s Disease Research

Molecular Neurodegeneration

Lena Brundin, M.D., Ph.D.

Professor, Department of Neurodegenerative Science

Behavioral Medicine

Gerhard (Gerry) Coetzee, Ph.D.

Professor, Department of Neurodegenerative Science; Director, MiND NeuroGenomes Project

Post-GWAS Functionality

Dr. Michael Henderson - Parkinson’s Research and Director of VAI Brain Bank

Michael Henderson, Ph.D.

Associate Professor, Department of Neurodegenerative Science; Director, VAI Brain Bank

Protein Pathologies and Genetic Risk in Neurodegeneration

Melissa Hoyer, Ph.D.

Assistant Professor, Department of Neurodegenerative Science

Neuronal Organelle Quality Control and Health

Laurent Roybon, Ph.D.

Associate Professor, Department of Neurodegenerative Science; Director, MiND iPSC Program

Patient-Based Models of Neurodegenerative Diseases

Qiang Zhu, Ph.D.

Assistant Professor, Department of Neurodegenerative Science

Genetics, Epigenetics and Therapeutic Innovation in Neurodegenerative Diseases

Affiliate Faculty

Yang Yang, Ph.D.

Assistant Professor, Department of Structural Biology

Structural Basis for Neurodegenerative Diseases

ADJUNCT FACULTY

Lucas Pozzo-Miller, Ph.D.

Adjunct Faculty, Neurodegenerative Science

Primary Institution: Michigan State University

WEST MICHIGAN NEURO­DEGENERATIVE DISEASE (MIND) PROGRAM TEAM

Darren Moore, Ph.D.

Chair and Professor, Department of Neurodegenerative Science; Director, MiND Program; Jay Van Andel Endowed Chair in Parkinson’s Disease Research

Molecular Neurodegeneration

Laurent Roybon, Ph.D.

Associate Professor, Department of Neurodegenerative Science; Director, MiND iPSC Program

Patient-Based Models of Neurodegenerative Diseases

Gerhard (Gerry) Coetzee, Ph.D.

Professor, Department of Neurodegenerative Science; Director, MiND NeuroGenomes Project

Post-GWAS Functionality

Dr. Michael Henderson - Parkinson’s Research and Director of VAI Brain Bank

Michael Henderson, Ph.D.

Associate Professor, Department of Neurodegenerative Science; Director, VAI Brain Bank

Protein Pathologies and Genetic Risk in Neurodegeneration

Erin Williams, Ph.D.

Research Program Manager, MiND

Jamie Durst, B.S.

Senior Administrative Assistant II, Department of Neurodegenerative Science

Olivia Licari

Research Technician, MiND Program

Recent Publications

Our Impact

We're raising thousands to save millions

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

  • 121 peer-reviewed papers published in 2023
  • 62 peer-reviewed papers published in high-impact journals in 2023
  • 55 clinical trials launched to date
Support VAI